PTO/SB/08a (08-03)
Approved for use through 97/31/2006, OMS 0651-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

	Application Number		
INFORMATION DIGGS COURS	Filing Date		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Tsuy		oshi HASEGAWA
(Not for submission under 37 CFR 1.99)	Art Unit	\neg	
(Not for Submission under or of it 1.00)	Examiner Name		
	Attorney Docket Number	-	60303.58/ho

					U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Da	ate	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines where int Passages or Release s Appear	
	1									
If you wis	h to a	dd additional U.S. Pate	nt citatio	n informa	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT A	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publicat Date	ion	Name of Pate of cited Docu	Relevan		Columns,Lines when int Passages or Rele s Appear	
	1									
If you wis	h to a	dd additional U.S. Publ		,		n information p		d button	Add	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	,	Kind Code4	Publication	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	+=
	1	2003-145290	JP		А	2003-05-20				Z
	2	3350667	JP		B2	2002-09-13				V
	3	1 068 924	EP		A1	2001-01-17				V

Application Number Fing Date First Named Inventor Touyosh HASEGAN/A AT Unit Laminer Name Attorner Docket Number S00033.581b

If you wis	h to a	dd add	ditional Foreign Patent Document citation information please click the Add button Add	_
			NON-PATENT LITERATURE DOCUMENTS Remove	_
Examiner of the initials* to No include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue num				
	1		mational Search Report issued in the corresponding International Application No. PCT/JP2004/019197, mailed on 19, 2005.	7
If you wis	h to a	dd add	ditional non-patent literature document citation information please click the Add button Add	_
			EXAMINER SIGNATURE	_
Examiner Signature Date Considered				_

1 See Kind Codes of USPTO Patent Documents at were USPTO_GOV or MPEP 901.64. ² Enter office that issued the document, by the ho-eleter code (WIPO Standard ST3.) ² For Juspanes plants concurrent, by manufactor of the year of the Temporar must precede the serial number of the plants of coursent. It was noticed to the document with or serial production of the year of the Temporar must precede the serial number of the plant document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language transitions in attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number Filing Date First Number Investor Touyonks HASEGAWA Art Unit Examiner Name Attorney Docket Number | 60303.581to

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the	appropriate selection	on(s):
---------------	----------	-------------	----------	-----------------------	--------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 1.97(eVI.)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(c) for the filing of the information disclosure statement. See 37 CFR 197(c) for the filing of the information disclosure statement. See 37 CFR 197(c) for the filing of the information disclosure statement. See 37 CFR 197(c) for the filing of the information disclosure statement. See 37 CFR 197(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_						
Signature	/Joseph R. Keating #37,368/	Date (YYYY-MM-DD)	2006-06-22			
Name/Print	Joseph R. Keating	Registration Number	37368			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.